Atjaunināt sīkdatņu piekrišanu

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications 2013 ed. [Hardback]

Edited by
  • Formāts: Hardback, 378 pages, height x width: 235x155 mm, weight: 746 g, X, 378 p., 1 Hardback
  • Sērija : Cancer Drug Discovery and Development
  • Izdošanas datums: 12-Dec-2012
  • Izdevniecība: Springer-Verlag New York Inc.
  • ISBN-10: 1461454557
  • ISBN-13: 9781461454557
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 136,16 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Standarta cena: 160,19 €
  • Ietaupiet 15%
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications 2013 ed.Palielināt
  • Formāts: Hardback, 378 pages, height x width: 235x155 mm, weight: 746 g, X, 378 p., 1 Hardback
  • Sērija : Cancer Drug Discovery and Development
  • Izdošanas datums: 12-Dec-2012
  • Izdevniecība: Springer-Verlag New York Inc.
  • ISBN-10: 1461454557
  • ISBN-13: 9781461454557
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9781461454557.html
Keywords:
This volume collets leading research on antibody-drug conjugates and immunotoxins. It examines all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
Part I Introduction and Development Perspectives
1 Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins
3(20)
Pamela A. Trail
2 Antibody-Drug Conjugate Development
23(18)
Aakanksha Khandelwal
Haleh Saber
Marjorie A. Shapiro
Hong Zhao
Part II Development of Antibody-Drug Conjugates
3 Assay Methodologies and Challenges
41(16)
Katherine R. Kozak
Helga Raab
4 Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates
57(20)
Sandhya Girish
Manish Gupta
5 Predictive Biomarkers for Antibody-Drug Conjugates
77(16)
David Dornan
Jeff Settleman
Part III Selection of Cytotoxic Agents
6 Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates
93(24)
Wayne C. Widdison
Ravi V.J. Chari
7 Linker Technology and Impact of Linker Design on ADC Properties
117(22)
Victor S. Goldmacher
Rajeeva Singh
Thomas Chittenden
Yelena Kovtun
Part IV Antibody-Drug Conjugates for Hematologic Malignancies
8 Antibody-Drug Conjugates for the Treatment of B-Cell Malignancies
139(10)
Andrew G. Polson
9 Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies
149(12)
John M. Lambert
Veronique Blanc
Nathalie Le Bail
Anne Bousseau
10 Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies
161(18)
Andres Forero
Christos Vaklavas
Albert F. LoBuglio
Part V Antibody-Drug Conjugates for Solid Tumors
11 Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer
179(32)
Hope S. Rugo
Ian E. Krop
Yu-Waye Chu
12 CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)
211(10)
Christos Vaklavas
Albert F. LoBuglio
Mansoor Saleh
Michael Yelin
Andres Forero
13 Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer
221(20)
Douglas Leipold
William G. Mallet
14 EphA2 Immunoconjugate
241(14)
Zhan Xiao
Dowdy Jackson
David A. Tice
15 Anti-PSMA Antibody-Drug Conjugates and Immunotoxins
255(18)
Philipp Wolf
16 Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine
273(24)
John M. Lambert
James O'Leary
Kathleen R. Whiteman
Victor S. Goldmacher
Part VI Metabolism
17 Studies on the Metabolism of Antibody-Drug Conjugates
297(22)
Xiuxia Sun
Hans Erickson
Part VII Immunotoxins
18 Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu
319(30)
Yu Cao
Michael G. Rosenblum
19 The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors
349(20)
Joycelyn Entwistle
Mark Kowalski
Jennifer Brown
Jeannick Cizeau
Glen C. MacDonald
Index 369